Built for the AI Decade. Built for Those Who Own the Domain.

AI in life sciences is not a horizontal technology problem. It is a deeply domain-intensive one. Every workflow is regulated. Every decision must be auditable. Every output is accountable to a patient. Generic foundation models cannot reason about an FDA labeling guideline, a Phase III endpoint, a payer dossier, or the semantics of a medico-legal review. What is required is a life sciences-native operating system - fusing 27 years of regulatory, therapeutic and commercial depth with a proprietary intelligent data layer and a fabric of AI agents engineered for the workflows that move molecules from lab to patient. This is the operating system Indegene has built. It is already running - at scale, in production - for the companies shaping the future of medicine.

A Life Sciences-Native Operating System - Four Layers, One Accountable Stack

Our operating system is not generic GenAI rebadged for pharma. It is a ground-up rethink of how regulated life sciences work is designed, executed, governed and continuously improved. It is engineered to deliver the outcomes our clients can measure on a board slide: submissions cleared faster and right-first-time, MLR cycles compressed from weeks to hours, adverse events processed at a fraction of historical cost and cycle time, HCP and patient engagement personalized in real time, and brand launches accelerated by months. Four interlocking layers make this possible.

Same 27-Year Domain Muscle. New Category Economics

This architecture makes Indegene accountable for outcomes - submission-readiness, launch speed, content compliance, engagement quality, revenue impact - not for hours or headcount. The economics reflect that shift: revenue growing several times faster than headcount, net revenue retention above 100% every year for the last 5 years, our top-20 client cohort tripled in revenue. The world’s leading life sciences companies are choosing Indegene as the strategic operating partner for their AI agenda - not as a vendor of effort, but as the accountable operator of the workflows that will define their next decade. We are already running the model the industry is moving toward. That is what it means to translate promise into performance.

Our Next Generation AI-embedded Solutions

While we continue embedding GenAI into all of the regulated workflows that we manage across the continuum of clinical, regulatory, safety, medical, market access and commercial operations, we have prioritized five operating models that are key for our clients to get their drugs to market faster, safer and cost effectively. Each is a structural rethink of a critical workflow that, until now, has been bound by manual effort, fragmented hand-offs, or compliance friction. These are the operating models that will define the next generation of life sciences enterprises.

• One-Click Submissions: Accelerating regulatory pathways through intelligent automation across authoring, review, publishing, and submission tracking, compressing what is today a multi-month effort into days
• Agentic AOR of the Future: Drastically reducing time from market insights to creative concepts and replacing fragmented, agency-led execution with platform-driven, modular content operations, where content is created once, governed centrally, and activated across markets and channels at enterprise scale
• Human-less MLR: Moving medical, legal, and regulatory review from a bottleneck into a near-instantaneous, agentic process that tightens compliance and control rather than loosening it
• Safety-in-a-Box: Human-light pharmacovigilance and drug safety operations that automate adverse event processing/monitoring, safety surveillance, reporting and signal detection
• AI-powered Omnichannel Engagement: Making every HCP and stakeholder interaction personalized and adaptive in real time, drawing on clinical, behavioral, and engagement data the moment it is generated - combined with years of interaction and affinity data that Indegene owns
• Intelligent Clinical Trial Operations: Synthesizing multifaceted data and signals (scientific, regulatory, pricing, medical, competitive, patient) to optimize clinical trial design and accelerating recruitment of patients in clinical trials through AI-powered analytics of real-world data

Each of these is being built into operations we already run for clients. The transition is gradual and deliberate. Our clients don’t need to change their existing technology stack; because we are inserting agentic capability into the workflows they already trust us with.

Our Key AI Products

Powered by Our Platform

Data Security and Privacy

Our information security management system continues to comply with ISO/IEC 27001:2013 and ISO/IEC 27701:2019. Internal protocols around data encryption, anonymization, pseudonymization, and PII handling are audited and tightened on an ongoing basis. Cortex is built to handle proprietary client data with strict separation and zero cross-pollination across engagements.

This foundation is reinforced by our industry-leading defense-in-depth cybersecurity architecture spanning Zero Trust principles, identity and access management, endpoint protection, privileged access controls, continuous monitoring through our 24×7 Security Operations Center, and security controls for cloud and GenAI workloads. Independent assessments continue to place Indegene among the highest-rated organizations in the industry for cybersecurity maturity, reflecting our quality-first approach to data security, robust privacy controls, and strong cyber risk governance.